The demonstration of EphB4 cancer-promoting effects in a variety of malignant cancer types [5, 13, 39] has provided the rational for targeting EphB4 as a mean to block its reverse signaling in the therapeutic setting [9, 40, 41]. Here, EPHB4 is linked to cancer.